Dr David L. Porter: Combining CAR-T Cells With Other Immunotherapies the Next Logical Step

Video

David L. Porter, MD, of the University of Pennsylvania Health System, explains why treating tumors with a combination of CAR-T cells and other immune-stimulating agents is a logical next step for investigators.

David L. Porter, MD, of the University of Pennsylvania Health System, explains why treating tumors with a combination of CAR-T cells and other immune-stimulating agents is a logical next step for investigators.

Transcript (slightly modified)

Can CAR-T cells be combined with other immunotherapies or targeted agents?

I think there is no doubt that CAR-T cells will ultimately be combined with other immunotherapies and other agents. There are years and years of precedent for combining different types of anti-cancer therapy. I do think there will be some cases where CAR-T cells are sufficient by themselves. We’ve seen that already in some of these B-cell malignancies and ALL [acute lymphoblastic leukemia] and some people with non-Hodgkin’s lymphoma or CLL [chronic lymphocytic leukemia].

But there will be situations where the CAR-T cells may not be effective by themselves, and there are some natural combinations one can start thinking of. For this to be effective, the T-cell has to be active, so combining the CAR-T cells with immune stimulating agents will be very, very logical: some of the checkpoint inhibitors, for instance.

There are clinical trials also now ongoing, combining CAR-T cells with medications like ibrutinib. Ibrutinib’s a very common therapy for CLL and some B-cell malignancies, and there is good laboratory data now that ibrutinib may make the CAR-T cells more effective at killing their target, at killing CLL cells for instance. And there’s data in the laboratory that it may make the CLL cells better targets for the T-cells to kill them. And so it’s another natural combination that I think investigators are thinking of testing.

And there are a number of other agents that one can think of to try and activate the T-cells when perhaps the body’s natural defenses are designed to keep the T-cells from becoming activated, or the cancer’s defenses are designed to keep the T-cells from getting into the tumor or from being activated. So I think there are a lot of possibilities, and we will see these trials being done over the next few years, combining CAR-T cells with other agents as well.

Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.